<DOC>
	<DOCNO>NCT01575795</DOCNO>
	<brief_summary>This multi-center , prospective , randomize , single-blind , investigator initiate , pharmacodynamic study parallel design , perform 3 institution ( Patras University Hospital ; Evangelismos Athens General Hospital ; Gennimatas Athens General Hospital ) . Patients ST elevation myocardial infarction ( symptom onset &lt; 12 hour ) , undergo primary percutaneous coronary intervention , antiplatelet naïve ( Group A ) present high residual PR ( define PRU ≥ 208 ) immediately primary percutaneous coronary intervention , randomize informed consent , 1:1 ratio either : Ticagrelor 180mg loading dose ( LD ) , follow 90mg x2 maintenance dose ( MD ) start 12±6 hour post LD Or Ticagrelor 360mg load dose ( LD ) , follow 90mg x2 maintenance dose ( MD ) start 12±6 hour post LD Platelet reactivity assessment perform randomization ( Hour 0 ) 0.5 , 1 , 2 , 4 hour randomization , use VerifyNow assay , platelet reactivity unit ( PRU ) . Documentation major adverse cardiac event ( death , myocardial infarction , stroke , urgent revascularization procedure PCI CABG ) bleeding ( accord Bleeding Academic Research Consortium criterion ) perform patient 's discharge .</brief_summary>
	<brief_title>Standard ( 180mg ) Versus Double ( 360mg ) Loading Dose Ticagrelor Patients With ST-elevation Myocardial Infarction ( STEMI ) , Undergoing Primary Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age ≥ 18 year old 2 . Patients STEMI ( onset pain &lt; 12 hour ) indication primary PCI 3 . Antiplatelet naïve present HTPR ( ≥ 208 PRU ) immediately primary percutaneous coronary intervention 4 . Informed consent obtain write Exclusion Criteria Pregnancy Breastfeeding Inability give inform consent high likelihood unavailable Day 5 Cardiogenic shock Major periprocedural complication ( death , stent thrombosis , vessel perforation , arrhythmia require cardioversion , temporary pacemaker insertion intravenous antiarrhythmic agent , respiratory failure require intubation , vascular injury ( arteriovenous shunt , retroperitoneal bleed ) , major bleeding ( need bood transfusion drop haemoglobin postPCI ≥ 5 gr/ dl intracranial bleeding ) . Unsuccessful PCI ( residual stenosis &gt; 30 % flow &lt; ΤΙΜΙ 3 ) Known hypersensitivity ticagrelor History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 3 month . Other bleed diathesis , consider investigator high risk bleed Any previous history stroke , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) . Thrombocytopenia ( &lt; 100.000/μL ) randomization Anaemia ( Hct &lt; 30 % ) randomization Polycytaemia ( Hct &gt; 52 % ) randomization Periprocedural IIb/IIIa inhibitor administration Thrombolysis administration Recent ( &lt; 6 week ) major surgery trauma , include GABG . Subjects receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor discontinue duration study . Concomitant oral IV therapy strong CY P3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazana vir , grapefruit juice N1 L/d ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , strong CYP3A inducer ( rifampin/rifampicin , phenytoin , carbamazepine ) . Increased risk bradycardiac event . Dialysis require . Severe uncontrolled chronic obstructive pulmonary disease Known severe hepatic impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>ST elevation acute myocardial infarction</keyword>
	<keyword>Platelet reactivity</keyword>
</DOC>